Application of stomach-regulating qi-supporting decoction in preparation of drugs for preventing and treating metabolic syndrome caused by olanzapine taken by schizophrenia patients

A technology for schizophrenia and olanzapine, applied in metabolic diseases, drug combinations, pharmaceutical formulations, etc., can solve problems such as no reports on Tiaowei Chengqi Decoction, and achieve the effects of low cost, easy preparation and less medicinal taste

Inactive Publication Date: 2020-09-01
SHANGHAI MENTAL HEALTH CENT (SHANGHAI PSYCHOLOGICAL COUNSELLING TRAINING CENT)
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] At present, there is no report on the use of Tiaowei Chengqi Decoction in the prev...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of stomach-regulating qi-supporting decoction in preparation of drugs for preventing and treating metabolic syndrome caused by olanzapine taken by schizophrenia patients
  • Application of stomach-regulating qi-supporting decoction in preparation of drugs for preventing and treating metabolic syndrome caused by olanzapine taken by schizophrenia patients
  • Application of stomach-regulating qi-supporting decoction in preparation of drugs for preventing and treating metabolic syndrome caused by olanzapine taken by schizophrenia patients

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0022] 1. Objects and methods

[0023] 1. Object

[0024] From August 2018 to February 2020, 72 hospitalized patients with first-episode or relapsed schizophrenia who developed metabolic syndrome after taking olanzapine were prospectively and continuously enrolled. The patients were randomly divided into the research group and the control group by simple randomization (random number table), with 38 cases in the research group and 34 cases in the control group.

[0025] Inclusion criteria: (1) Meet the ICD-10 diagnostic criteria for schizophrenia; (2) Meet the hyperactivity of stomach heat type in TCM internal medicine: A. Main symptoms: obesity, eating too much, easy to be hungry, easy to fatigue; B. Dialectical Main points: drinking due to thirst, red tongue with yellow dry coating, strong and strong pulse; C. Accompanying symptoms: epigastric dysphoria, dry stool, and constipation. (3) Meet the diagnostic criteria recommended by the Chinese Medical Association for metaboli...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to an application of stomach-regulating qi-supporting decoction in preparation of a medicine for preventing and treating metabolic syndrome caused by olanzapine taken by schizophrenia patients. Clinical experiments prove that the curative effect and safety of the stomach-regulating qi-supporting decoction for treating metabolic syndrome caused by taking olanzapine by schizophrenia patients are evaluated; results show that compared with metformin, the stomach-regulating qi-supporting decoction can better improve weight and waistline increase caused by taking olanzapine byschizophrenia patients, reduce glycosylated hemoglobin and reduce side effects; the stomach-regulating qi-supporting decoction has a prevention effect on disorder of various indexes of blood fat caused by taking olanzapine. The invention provides a new effective means for preventing and treating metabolic syndrome caused by taking olanzapine by clinical schizophrenia patients.

Description

technical field [0001] The invention relates to the field of traditional Chinese medicine compositions, in particular to the application of Tiaowei Chengqi decoction in the preparation of medicines for preventing and treating metabolic syndrome caused by olanzapine taken by patients with schizophrenia. Background technique [0002] Antipsychotic drugs are the main treatment drugs for patients with schizophrenia, but most of them, especially the second-generation antipsychotic drugs, often cause weight gain, glucose and lipid metabolism disorders, etc., which can lead to metabolic syndrome. About one-third of people with schizophrenia have metabolic syndrome, and 69 percent of those with chronic disease [1] . Prevalence of obesity, type 2 diabetes and hypercholesterolemia estimated to be 3-5 times higher in schizophrenia than in general population [2] . People with schizophrenia are twice as likely to be diagnosed with heart disease and die compared with the general popula...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K36/708A61P3/00A61K33/04
CPCA61K33/04A61K36/484A61K36/708A61P3/00A61K2300/00
Inventor 朱丽萍龙彬赵静张建明陆颖陈妍
Owner SHANGHAI MENTAL HEALTH CENT (SHANGHAI PSYCHOLOGICAL COUNSELLING TRAINING CENT)
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap